New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.73
5.22
+1.84%
Follow ABBV
Alert me
Revenue to profit Fiscal 2025, year to Dec 31, 2025
Of every $100 of revenue, $6.92 was left as profit. Gross margin has risen two years running, from 62.4% to 70.2%. What is an income statement?
| Revenue | 61.2 | 100.0% |
|---|---|---|
| Cost of revenue | −18.2 | −29.8% |
| Gross profit | 43.0 | 70.2% |
| Research & development | −9.1 | −14.9% |
| Selling, general & admin | −14.0 | −22.9% |
| Other operating costs | −4.8 | −7.8% |
| Operating income | 15.1 | 24.6% |
| Other income, net | −8.5 | −13.9% |
| Income tax | −2.4 | −3.9% |
| Net income | 4.2 | 6.9% |
Net margin (right axis)
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6B | $28.2B | $32.8B | $33.3B | $45.8B | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Operating income | $9.3B | $9.5B | $6.4B | $13.0B | $11.4B | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net income | $6.0B | $5.3B | $5.7B | $7.9B | $4.6B | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Net margin (right axis) | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.6% | 20.4% | 9.0% | 7.6% | 6.9% |
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
25,638.00 | 28,216.00 | 32,753.00 | 33,266.00 | 45,804.00 | 56,197.00 | 58,054.00 | 54,318.00 | 56,334.00 | 61,160.00 |
Revenue Growth |
12.16% | 10.06% | 16.08% | 1.57% | 37.69% | 22.69% | 3.30% | (6.44%) | 3.71% | 8.57% |
Cost of Revenue |
5,832.00 | 7,042.00 | 7,718.00 | 7,439.00 | 15,387.00 | 17,446.00 | 17,414.00 | 20,415.00 | 16,904.00 | 18,204.00 |
Gross Profit |
19,806.00 | 21,174.00 | 25,035.00 | 25,827.00 | 30,417.00 | 38,751.00 | 40,640.00 | 33,903.00 | 39,430.00 | 42,956.00 |
R&D Expenses |
4,385.00 | 5,007.00 | 10,329.00 | 6,407.00 | 6,379.00 | 6,922.00 | 6,510.00 | 7,675.00 | 12,791.00 | 9,096.00 |
SG&A Expenses |
5,881.00 | 6,295.00 | 7,399.00 | 6,942.00 | 11,299.00 | 12,349.00 | 15,260.00 | 12,872.00 | 14,752.00 | 14,010.00 |
Operating Income |
9,340.00 | 9,545.00 | 6,383.00 | 12,983.00 | 11,363.00 | 17,924.00 | 18,117.00 | 12,757.00 | 9,137.00 | 15,075.00 |
Non-operating Income/Expense |
(1,456.00) | (1,818.00) | (1,186.00) | (4,557.00) | (7,965.00) | (4,935.00) | (4,640.00) | (6,507.00) | (5,421.00) | (8,478.00) |
Non-operating Interest Expenses |
965.00 | 1,004.00 | 1,144.00 | 1,509.00 | 2,280.00 | 2,384.00 | 2,044.00 | 1,684.00 | 2,160.00 | 2,627.00 |
| 7,884.00 | 7,727.00 | 5,197.00 | 8,426.00 | 3,398.00 | 12,989.00 | 13,477.00 | 6,250.00 | 3,716.00 | 6,597.00 | |
Income Tax Provision |
1,931.00 | 2,418.00 | (490.00) | 544.00 | (1,224.00) | 1,440.00 | 1,632.00 | 1,377.00 | (570.00) | 2,364.00 |
Income after Tax |
5,953.00 | 5,309.00 | 5,687.00 | 7,882.00 | 4,622.00 | 11,549.00 | 11,845.00 | 4,873.00 | 4,286.00 | 4,233.00 |
Dividends (Preferred) |
— | — | — | — | — | — | 54.00 | 43.00 | 40.00 | 40.00 |
Non-Controlling Interest |
— | — | — | — | 6.00 | 7.00 | 9.00 | 10.00 | 8.00 | 7.00 |
Net Income Common |
5,953.00 | 5,309.00 | 5,687.00 | 7,882.00 | 4,616.00 | 11,542.00 | 11,782.00 | 4,820.00 | 4,238.00 | 4,186.00 |
EPS (Basic) |
3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
EPS (Diluted) |
3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
Shares (Basic, Weighted) |
1,622.00 | 1,596.00 | 1,541.00 | 1,481.00 | 1,667.00 | 1,770.00 | 1,771.00 | 1,768.00 | 1,769.00 | 1,769.00 |
Shares (Diluted, Weighted) |
1,631.00 | 1,603.00 | 1,546.00 | 1,484.00 | 1,673.00 | 1,777.00 | 1,778.00 | 1,773.00 | 1,773.00 | 1,773.00 |
Gross Margin |
77.25% | 75.04% | 76.44% | 77.64% | 66.41% | 68.96% | 70.00% | 62.42% | 69.99% | 70.24% |
EBIT Margin |
36.43% | 33.83% | 19.49% | 39.03% | 24.81% | 31.89% | 31.21% | 23.49% | 16.22% | 24.65% |
EBT margin |
30.75% | 27.39% | 15.87% | 25.33% | 7.42% | 23.11% | 23.21% | 11.51% | 6.60% | 10.79% |
Net Profit Margin |
23.22% | 18.82% | 17.36% | 23.69% | 10.08% | 20.54% | 20.29% | 8.87% | 7.52% | 6.84% |
Free Cash Flow Margin |
25.59% | 33.42% | 39.05% | 38.39% | 36.66% | 39.13% | 41.77% | 40.62% | 31.65% | 29.13% |
EBITDA |
10,529.00 | 11,046.00 | 8,148.00 | 15,000.00 | 17,834.00 | 26,445.00 | 26,584.00 | 25,684.00 | 21,999.00 | 24,061.00 |
EBIT |
9,340.00 | 9,545.00 | 6,383.00 | 12,983.00 | 11,363.00 | 17,924.00 | 18,117.00 | 12,757.00 | 9,137.00 | 15,075.00 |
Income from Continuous Operations |
5,953.00 | 5,309.00 | 5,687.00 | 7,882.00 | 4,622.00 | 11,549.00 | 11,845.00 | 4,873.00 | 4,286.00 | 4,233.00 |
Consolidated Net Income/Loss |
5,953.00 | 5,309.00 | 5,687.00 | 7,882.00 | 4,622.00 | 11,549.00 | 11,845.00 | 4,873.00 | 4,286.00 | 4,233.00 |
EPS (Basic, from Continuous Ops) |
3.67 | 3.33 | 3.69 | 5.32 | 2.77 | 6.52 | 6.69 | 2.76 | 2.42 | 2.39 |
EPS (Basic, Consolidated) |
3.67 | 3.33 | 3.69 | 5.32 | 2.77 | 6.52 | 6.69 | 2.76 | 2.42 | 2.39 |
EPS (Diluted, from Cont. Ops) |
3.65 | 3.31 | 3.68 | 5.31 | 2.76 | 6.50 | 6.66 | 2.75 | 2.42 | 2.39 |
Shares (Diluted, Average) |
1,631.00 | 1,603.00 | 1,546.00 | 1,484.00 | 1,673.00 | 1,777.00 | 1,778.00 | 1,773.00 | 1,773.00 | 1,773.00 |
EPS (Diluted, Consolidated) |
3.65 | 3.31 | 3.68 | 5.31 | 2.76 | 6.50 | 6.66 | 2.75 | 2.42 | 2.39 |
EBITDA Margin |
41.07% | 39.15% | 24.88% | 45.09% | 38.94% | 47.06% | 45.79% | 47.28% | 39.05% | 39.34% |
Operating Cash Flow Margin |
27.46% | 35.30% | 40.99% | 40.05% | 38.40% | 40.53% | 42.97% | 42.05% | 33.38% | 31.12% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026